Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 1 Study Of Pf-05082566 As A Single Agent In Patients With Advanced Cancer, And In Combination With Rituximab In Patients With Non-hodgkin's Lymphoma (Nhl)

Trial Profile

A Phase 1 Study Of Pf-05082566 As A Single Agent In Patients With Advanced Cancer, And In Combination With Rituximab In Patients With Non-hodgkin's Lymphoma (Nhl)

Status: Completed
Phase of Trial: Phase I

Latest Information Update: 22 Apr 2022

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Rituximab (Primary) ; Utomilumab (Primary)
  • Indications Advanced breast cancer; B-cell lymphoma; Bladder cancer; Chronic lymphocytic leukaemia; Colorectal cancer; Diffuse large B cell lymphoma; Follicular lymphoma; Gastric cancer; Gastrointestinal stromal tumours; Head and neck cancer; Hodgkin's disease; Liver cancer; Lung cancer; Malignant melanoma; Mantle-cell lymphoma; Marginal zone B-cell lymphoma; Nasopharyngeal cancer; Neuroendocrine carcinoma; Non-Hodgkin's lymphoma; Non-small cell lung cancer; Ovarian cancer; Pancreatic cancer; Renal cell carcinoma; Skin cancer; Soft tissue sarcoma; Solid tumours; Squamous cell cancer
  • Focus Adverse reactions; First in man
  • Sponsors Pfizer
  • Most Recent Events

    • 18 Mar 2022 Results from NCT01307267, NCT02179918 and NCT02444793 comparing the anti drug antibody of utomilumab and its impact on the PK, safety, and efficacy in patients with advanced cancer, presented at the 123rd Annual Meeting of the American Society for Clinical Pharmacology and Therapeutics
    • 06 Mar 2020 Results (n=67) evaluating safety, pharmacokinetics, clinical activity, and pharmacodynamics of treatment with utomilumab plus rituximab in patients with relapsed/refractory follicular (FL) and other CD20(+) non-Hodgkin lymphomas (NHLs) published in the Clinical Cancer Research
    • 19 Mar 2019 Status changed from active, no longer recruiting to completed.
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top